[1]黎明,李勇,黄召,等.Serabelisib抗人肝母细胞瘤HepG2细胞的作用及其机制探讨[J].临床小儿外科杂志,2020,19(05):410-414.[doi:10.3969/j.issn.1671-6353.2020.05.007]
 Li Ming,Li Yong,Huang Zhao,et al.Effect of Serabelisib on human hepatoblastoma HepG2 cells and its mechanisms[J].Journal of Clinical Pediatric Surgery,2020,19(05):410-414.[doi:10.3969/j.issn.1671-6353.2020.05.007]
点击复制

Serabelisib抗人肝母细胞瘤HepG2细胞的作用及其机制探讨

参考文献/References:

1 金晟,施诚仁.儿童肝母细胞瘤研究现状[J].临床儿科杂志,2014,32(10):988-992.DOI:10.3969/j.issn.1000-3606.2014.10.31. Jin S,Shi CR.Current research status of pediatric hepatoblastoma[J].Journal of Clinical Pediatrics,2014,32(10):988-992.DOI:10.3969/j.issn.1000-3606.2014.10.31.
2 Lim I,Bondoc AJ,Geller JI,et al.Hepatoblastoma-the evolution of biology,surgery,and transplantation[J].Children (Basel),2018,6(1):E1.DOI:10.3390/children6010001.
3 Trobaugh-Lotrario AD,Katzenstein HM.Chemotherapeutic a-pproaches for newly diagnosed hepatoblastoma:past,present,and future strategies[J].Pediatr Blood Cancer,2012,59(5):809-812.DOI:10.1002/pbc.24219.
4 李勇,肖雅玲,陈朝晖,等.姜黄素对人肝母细胞瘤细胞株HepG2增殖和转移的影响[J].中国普通外科杂志,2014,23(1):117-120.DOI:10.7659/j.issn.1005-6947.2014.01.023. Li Y,Xiao YL,Chen ZH,et al.Effects of Curcumin on proliferation and metastasis of human hepatoblastoma cell line HepG2 in vitro[J].Chin J Gen Surg,2014,23(1):117-120.DOI:10.7659/j.issn.1005-6947.2014.01.023.
5 Marin J,Briz O,Herraez E,et al.Molecular bases of the poor response of liver cancer to chemotherapy[J].Clin Res Hepatol Gastroenterol,2018,42(3):182-192.DOI:10.1016/j.clinre.2017.12.006.
6 Vivanco I,Sawyers CL.The phosphatidylinositol 3-Kinase AKT pathway in human cancer[J].Nat Rev Cancer,2002,2(7):489-501.DOI:10.1038/nrc839.
7 Osaki M,Oshimura M,Ito H.PI3K-Akt pathway:its functions and alterations in human cancer[J].Apoptosis,2004,9(6):667-676.DOI:10.1023/B:APPT.0000045801.15585.dd.
8 Liang J,Slingerland JM.Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression[J].Cell Cycle,2003,2(4):339-345.
9 Janku F,Yap TA,Meric-Bernstam F.Targeting the PI3K pathway in cancer:are we making headway?[J].Nat Rev Clin Oncol,2018,15(5):273-291.DOI:10.1038/nrclinonc.2018.28.
10 Alzahrani AS.PI3K/Akt/mTOR inhibitors in cancer:At the bench and bedside[J].Semin Cancer Biol,2019,59:125-132.DOI:10.1016/j.semcancer.2019.07.009.
11 Arends MJ,Wyllie AH.Apoptosis:mechanisms and roles in pathology[J].Int Rev Exp Pathol,1991,32(32):223-254.DOI:10.1016/b978-0-12-364932-4.50010-1.
12 Rybczynska AA,Boersma HH,de Jong S,et al.Avenues to molecular imaging of dying cells:Focus on cancer[J].Med Res Rev,2018,38(6):1713-1768.DOI:10.1002/med.21495.
13 Ucker DS,Levine JS.Exploitation of apoptotic regulation in cancer[J].Front Immunol,2018,27(9):241.DOI:10.3389/fimmu.2018.00241.
14 Boice A,Bouchier-Hayes L.Targeting apoptotic caspases in cancer[J].Biochim Biophys Acta Mol Cell Res,2020,1867(6):118688.DOI:10.1016/j.bbamcr.2020.118688.
15 Rai N,Sarkar M,Raha S.Piroxicam,a traditional non-steroidal anti-inflammatory drug (NSAID) causes apoptosis by ROS mediated Akt activation[J].Pharmacol Rep,2015,67(6):1215-1223.DOI:10.1016/j.pharep.2015.05.012.
16 Jiang C,Ma S,Hu R,et al.Effect of CXCR4 on apoptosis in osteosarcoma cells via the PI3K/Akt/NF-κβ signaling pathway[J].Cell Physiol Biochem,2018,46(6):2250-2260.DOI:10.1159/000489593.
17 Hartmann W,Küchler J,Koch A,et al.Activation of phosphatidylinositol-3’-kinase/AKT signaling is essential in hepatoblastoma survival[J].Clin Cancer Res,2009,15(14):4538-4545.DOI:10.1158/1078-0432.CCR-08-2878.
18 Xia Z,Zhang N,Ding D.Proliferation and migration of hepatoblastoma cells are mediated by IRS-4 via PI3K/Akt pathways[J].Int J Clin Exp Med,2014,7(10):3763-3769.
19 Juric D,de Bono JS,LoRusso PM,et al.A first-in-human,phase I,dose-escalation study of TAK-117,a selective PI3Kα isoform inhibitor,in patients with advanced solid malignancies[J].Clin Cancer Res,2017,23(17):5015-5023.DOI:10.1158/1078-0432.CCR-16-2888.
20 Patel CG,Rangachari L,Patti M,et al.Characterizing the sources of pharmacokinetic variability for TAK-117 (Serabelisib),an investigational phosphoinositide 3-kinase alpha inhibitor:a clinical biopharmaceutics study to inform development strategy[J].Clin Pharmacol Drug Dev,2019,8(5):637-646.DOI:10.1002/cpdd.613.

相似文献/References:

[1]高会江,董蒨,江布先,等.26例婴儿肝脏肿瘤的临床与病理相关性分析[J].临床小儿外科杂志,2010,9(06):422.
 GAO Hui jiang,DONG Qian,JIANG Bu xian,et al.Clinicopathological correlative analysis in infants with liver tumor.[J].Journal of Clinical Pediatric Surgery,2010,9(05):422.
[2]宋非无 李笃妙 吴强. 归脾汤治疗肝母细胞瘤22例疗效观察[J].临床小儿外科杂志,2012,11(05):373.
 [J].Journal of Clinical Pediatric Surgery,2012,11(05):373.
[3]乔国梁 李龙 葛军涛. 累及第二、三肝门巨大肝母细胞瘤手术切除41例[J].临床小儿外科杂志,2014,13(02):99.
[4]赵静,董蒨周显军.基于计算机辅助手术系统的儿童肝脏肿瘤与门静脉关系的影像学分析[J].临床小儿外科杂志,2017,16(06):546.
[5]彭宇明 尹 强 高红强 陈立健 袁妙贤.吲哚菁绿荧光染色引导下解剖性右半肝切除治疗儿童肝脏肿瘤[J].临床小儿外科杂志,2018,17(07):0.[doi:10.3969/j.issn.1671-6353.2018. 201805057]
 Peng Yumin,Yin Qiang,Gao Hongqiang,et al.Anatomic right-half of indocyanine green fluorescent staining hepatectomy for children with liver tumors.[J].Journal of Clinical Pediatric Surgery,2018,17(05):0.[doi:10.3969/j.issn.1671-6353.2018. 201805057]
[6]彭宇明,尹强,高红强,等.吲哚菁绿荧光染色引导下解剖性右半肝切除治疗儿童肝脏肿瘤[J].临床小儿外科杂志,2018,17(08):597.
 Peng Yumin,Yin Qiang,Gao Hongqiang,et al.Anatomic righthalf of indocyanine green fluorescent staining hepatectomy for children with liver tumors.[J].Journal of Clinical Pediatric Surgery,2018,17(05):597.
[7]袁妙贤,尹强,刘朝阳.肝脏中叶切除术治疗小儿肝脏肿瘤的疗效与安全性分析[J].临床小儿外科杂志,2019,18(10):859.[doi:10.3969/j.issn.1671-6353.2019.10.012]
 Yuan Miaoxian,Yin Qiang,Liu Chaoyang.Experience of mesohepatectomy in the treatment of hepatic tumors in children[J].Journal of Clinical Pediatric Surgery,2019,18(05):859.[doi:10.3969/j.issn.1671-6353.2019.10.012]
[8]郑百俊,程继文,高亚,等.腹腔镜肝切除术与开腹肝切除术治疗肝母细胞瘤的临床效果比较[J].临床小儿外科杂志,2019,18(11):935.[doi:10.3969/j.issn.1671—6353.2019.11.008]
 Zheng Baijun,Cheng Jiwen,Gao Ya,et al.Safety,feasibility and short-term outcome of laparoscopic liver resection versus open liver resection for hepatoblastoma[J].Journal of Clinical Pediatric Surgery,2019,18(05):935.[doi:10.3969/j.issn.1671—6353.2019.11.008]
[9]姚伟,董岿然,李凯,等.肝肿瘤切除术治疗POST-TEXT Ⅲ期和Ⅳ期肝母细胞瘤的中长期疗效分析[J].临床小儿外科杂志,2020,19(05):386.[doi:10.3969/j.issn.1671-6353.2020.05.003]
 Yao Wei,Dong Kuiran,Li Kai,et al.Efficacies of extended hepatic resection for POST-TEXT Ⅲ/Ⅳ hepatoblastoma[J].Journal of Clinical Pediatric Surgery,2020,19(05):386.[doi:10.3969/j.issn.1671-6353.2020.05.003]
[10]杨维,任清华,秦红,等.儿童肝母细胞瘤精准肝切除手术效果评价[J].临床小儿外科杂志,2020,19(05):392.[doi:10.3969/j.issn.1671-6353.2020.05.004]
 Yang Wei,Ren Qinghua,Qin Hong,et al.Evaluations of precise hepatectomy for pediatric hepatoblastoma[J].Journal of Clinical Pediatric Surgery,2020,19(05):392.[doi:10.3969/j.issn.1671-6353.2020.05.004]

备注/Memo

收稿日期:2020-03-18。
基金项目:湖南省卫生健康委课题(编号:C2019021);湖南省出生缺陷协同防治科技重大专项(编号:2019SK1010)
作者简介:黎明,Email:dawn1212@sina.com

更新日期/Last Update: 1900-01-01